Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.36 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20126173 | 0.90 | HRH3 (0.37) | HRH3NPC1RAB9ASLC2A1S1PR3 | |
| SCHEMBL20126340 | 0.88 | SPHK1 (0.40) | HRH3SPHK1 | |
| SCHEMBL20126274 | 0.83 | SPHK1 (0.34) | NPC1RAB9AS1PR3TP53MEN1 | |
| SCHEMBL20126277 | 0.81 | HRH3 (0.47) | HRH3MEN1KMT2ALMNASPHK1 | |
| SCHEMBL20126286 | 0.80 | HRH3 (0.47) | HRH3TP53KMT2ASPHK1 | |
| SCHEMBL20126218 | 0.80 | SPHK1 (0.36) | HRH3NPC1RAB9AS1PR3TP53 | |
| SCHEMBL20126315 | 0.78 | SPHK1 (0.36) | HRH3SPHK1 | |
| SCHEMBL20126259 | 0.77 | HRH3 (0.40) | HRH3NPC1RAB9ATP53MEN1 | |
| SCHEMBL20126246 | 0.77 | HRH3 (0.37) | HRH3MEN1KMT2ALMNASPHK1 | |
| SCHEMBL20126251 | 0.75 | ALDH1A1 (0.39) | HRH3NPC1RAB9ATP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-10 | — | — | US | disclosed |
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, PLD1, DRD2 | HRH3 85/4885NPC1 4011/4885RAB9A 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.